Marijuana Reclassification Shocks: Schedule I to III

President Trump just accelerated what may be the most significant shift in American drug policy since Richard Nixon signed the Controlled Substances Act into law over half a century ago.

Story Snapshot

Trump signed an executive order expediting marijuana’s reclassification from Schedule I to Schedule III, ending its designation alongside heroin and LSD
The reclassification acknowledges medical legitimacy while maintaining federal recreational prohibition, affecting 40 states with medical programs and 24 with recreational legalization
State-licensed cannabis businesses will gain previously prohibited tax deductions, while researchers will access expanded opportunities for medical studies
The policy shift began under Biden in 2022 but stalled in administrative processes until Trump’s December 2025 directive demanded expedited completion

From Nixon’s War on Drugs to Trump’s Tax Relief

Marijuana has occupied the federal government’s most restrictive drug category since 1970, classified as having no accepted medical use and high abuse potential. This placed cannabis in the same regulatory category as heroin, LSD, and ecstasy. The designation created a peculiar American contradiction: state-licensed dispensaries operating legally under state law while violating federal statutes. Forty states approved medical marijuana programs, and 24 legalized recreational use, yet federal prohibition remained unchanged. The federal government chose not to crack down on state-licensed businesses, creating a regulatory limbo that frustrated state officials, business owners, and patients alike.

The Biden Blueprint That Trump Completed

The reclassification journey began in October 2022 when President Biden requested the Department of Health and Human Services and Drug Enforcement Administration review marijuana’s scheduling. HHS recommended Schedule III status in August 2023, citing credible scientific support for treating pain, anorexia, and chemotherapy-induced nausea. The FDA and National Institute on Drug Abuse concurred. The Attorney General issued a proposed rule in May 2024, and the DEA announced administrative hearings in August. Nearly 43,000 public comments flooded in. Then the process stalled. Trump’s December 2025 executive order directed the Attorney General to complete rulemaking in the most expeditious manner, breaking the administrative logjam.

Follow the Money and the Medicine

The reclassification delivers tangible financial relief to an industry operating under crippling tax burdens. Federal law prohibits businesses selling Schedule I substances from claiming certain tax deductions, forcing state-licensed dispensaries to pay effective tax rates that would bankrupt most conventional retailers. Schedule III status removes this barrier, enabling standard business deductions. Vince C. Ning, co-CEO of cannabis wholesale platform Nabis, identified the immediate benefits: accelerated research, reduced stigma, new investment, and eased tax burdens. Cannabis stocks rose on the reclassification news, signaling investor confidence that institutional capital previously deterred by Schedule I status might finally flow into the sector.

Medical Research Breaks Free From Regulatory Handcuffs

Schedule I classification severely restricted medical research, creating a circular problem: marijuana remained Schedule I because it lacked accepted medical use, yet researchers struggled to establish medical use because Schedule I status blocked comprehensive studies. The FDA found credible scientific support for marijuana treating pain, anorexia related to certain medical conditions, and chemotherapy-induced nausea and vomiting. Schedule III status enables expanded research previously impossible under federal restrictions. Medical professionals attended Trump’s signing ceremony, recognizing the potential for FDA-approved cannabis-derived medications developed through rigorous clinical trials. The reclassification represents federal acknowledgment of what doctors and patients in 40 states already knew: marijuana possesses legitimate therapeutic applications.

The Regulatory Minefield Ahead

The Ohio State Moritz Law School’s Drug Enforcement and Policy Center warned that the next six to twelve months could be among the most transformative for the cannabis industry, but progress will likely come with regulatory confusion, conflicts of federal laws, and unintended consequences. Recreational use remains federally illegal despite reclassification, maintaining a bifurcated legal landscape. State governments retain regulatory authority within federal constraints, but the precise boundaries remain unclear during the transition period. The executive order directs expedited completion, yet administrative law hearing processes continue. The Attorney General holds implementation power, the DEA must finalize technical rulemaking, and 40 state medical programs plus 24 recreational programs must align operations with new federal classifications.

What Conservatives Should Recognize

This policy evolution embodies conservative principles often overlooked in drug policy debates: federalism, limited government intrusion, and evidence-based regulation. States demonstrated their laboratories-of-democracy function, implementing diverse marijuana policies while the federal government maintained outdated prohibition. The reclassification doesn’t mandate recreational legalization but removes federal barriers preventing states from regulating marijuana as they determine appropriate. It reduces tax burdens on legal businesses and enables medical research without imposing top-down mandates. The bipartisan trajectory from Biden’s initiation to Trump’s acceleration suggests rare common ground: acknowledging scientific evidence, respecting state authority, and eliminating counterproductive federal restrictions. Ning identified the next transformation: removing interstate commerce barriers between states, which would complete the federalist vision of state-level regulation without federal obstruction.

The Unfinished Cannabis Agenda

Reclassification resolves some contradictions but leaves others intact. Recreational prohibition remains federal law, creating continued tension with 24 state recreational programs. Banking access for cannabis businesses remains complicated by federal regulations. Interstate commerce restrictions prevent state-licensed producers from shipping across state lines, fragmenting the market and increasing costs. The Schedule III designation acknowledges medical legitimacy but doesn’t grant marijuana the same regulatory status as alcohol or tobacco, which aren’t scheduled substances at all. Industry leaders view reclassification as transformative yet recognize it as a waypoint rather than a destination. The cannabis industry secured tax relief and research access, yet comprehensive federal reform addressing banking, interstate commerce, and recreational legalization remains on the distant horizon.